Building on its flagship anticancer agent, TS-1, for which it has established evidence for various kinds of cancers, especially gastric cancer, Taiho Pharmaceutical has been conducting
research and development of drugs in new categories based on its accumulated findings and knowhow. One strong result was the discovery of LONSURF, which has a novel mechanism of
action. Taiho Pharmaceutical seeks to contribute to the diversification of cancer treatment around the world. It works on molecular targeted anticancer agents with various mechanisms such as inhibition of protein functions involved in cancer proliferation, survival, angiogenesis or drug resistance, as well as anticancer agents that target cancer cell-specific metabolism and also cancer immunity, an area that has developed remarkably in recent years.
Applying the experience and technology for molecular targeted drug discovery developed over years of oncology research, Taiho Pharmaceutical is dedicated itself to research in the allergy and immunology fields. The company pursues drugs with a focus on the mechanisms of refractory diseases such as autoimmune diseases, as well as drugs with novel mechanisms of action applicable to rare diseases.
Leveraging the wealth of findings and experience gained from BUP-4, a therapeutic agent for urinary incontinence and frequent urination, Taiho Pharmaceutical has researched the pathology behind many kinds of urinary incontinence and disorders of micturition. Taking advantage of this experience, Taiho Pharmaceutical is exploring new types of drugs for unmet medical needs.